Search research articles
Contact Us
Filters
Showing results (81-90 of 182) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2012
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
Kevin P Weinfurt, Damon M Seils, Li Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E G Chiorean, H I Hurwitz, R B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2008
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
Axel Grothey, Eric E Hedrick, Robert D Mass, et al.
Investigational New Drugs
|
October 12, 2012
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
Maja J A de Jonge, Paul Hamberg, Jaap Verweij, et al.
Molecular Cancer Therapeutics
|
July 13, 2018
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Yingmiao Liu, Mark D Starr, John C Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2005
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
S N Holden, S G Eckhardt, R Basser, et al.
Anticancer Research
|
January 2, 2010
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors
Elizabeth Dugan, Roxanne Truax, Kellen L Meadows, et al.
International Journal of Gastrointestinal Cancer
|
March 13, 2003
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
Michael A Morse, Smita K Nair, David Boczkowski, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
April 2, 2014
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study
H I Hurwitz, T S Bekaii-Saab, J C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2014
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Stephanie M Cushman, Chen Jiang, Ace J Hatch, et al.
Page
of 19
Search research articles
Search
Showing results (81-90 of 182) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2012
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
Kevin P Weinfurt, Damon M Seils, Li Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E G Chiorean, H I Hurwitz, R B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2008
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
Axel Grothey, Eric E Hedrick, Robert D Mass, et al.
Investigational New Drugs
|
October 12, 2012
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
Maja J A de Jonge, Paul Hamberg, Jaap Verweij, et al.
Molecular Cancer Therapeutics
|
July 13, 2018
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Yingmiao Liu, Mark D Starr, John C Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2005
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
S N Holden, S G Eckhardt, R Basser, et al.
Anticancer Research
|
January 2, 2010
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors
Elizabeth Dugan, Roxanne Truax, Kellen L Meadows, et al.
International Journal of Gastrointestinal Cancer
|
March 13, 2003
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
Michael A Morse, Smita K Nair, David Boczkowski, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
April 2, 2014
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study
H I Hurwitz, T S Bekaii-Saab, J C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2014
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Stephanie M Cushman, Chen Jiang, Ace J Hatch, et al.
Page
of 19